The derivative 6‐bromotryptamine A has been demonstrated to inhibit the activity of acetylcholinesterase in vitro and prevent scopolamine‐induced short‐term cognitive impairments in mice, thereby alleviating two main pathological events in the progress of Alzheimer's disease.[41] Therefore, the biosynthesis of 6‐bromotryptamine in S. cerevisiae would offer an alternative to the current chemical synthesis methods.[41] Similarly, 5‐bromotryptamine could be converted to 5‐bromo‐DMT, a metabolite found in marine sponges that has sedative properties.[42]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.